Summary. Glycation of long-lived proteins is an inevitable consequence of aging that is accelerated in patients with diabetes mellitus. Treatment of demineralized bone matrix particles from 35-week-old normal Long-Evans rats with glycolaldehyde, a precursor of advanced glycation end-products, was used to assess the effects of bone-matrix glycation on the process of bone differentiation. Matrix was incubated in phosphate buffered saline alone, phosphate buffered saline containing glycolaldehyde, glycolaldehyde plus the advanced glycation product-inhibitor aminoguanidine, or glycolaldehyde plus the advanced glycation product-inhibitor sodium cyanoborohydride. Glycolaldehyde increased the matrix advanced glycation product content as measured by specific fluorescence more than two-fold, while inhibiting bone differentiation more than 90 % as measured by in vivo 45CAC12 uptake, alkaline phosphatase levels, and histology. In contrast, simultaneous incubation with the advanced glycation product-inhibitor aminoguanidine or sodium cyanoborohydride not only reduced fluorescence to normal, but also restored bone differentiation. Furthermore, the inhibition of bone differentiation by glycolaldehyde was not reversed by subsequent application of recombinant bone morphogenetic protein-2. These observations suggest that formation of advanced glycation products on bone matrix alters its ability to induce bone formation, and probably involves alterations of binding sites for extractable proteins with direct bone inductive properties such as bone morphogenetic protein-2. Decreased bone formation associated with aging and diabetes may result, in part, from advanced glycation product formation on matrix proteins.
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Aging and diabetes mellitus are each associated with changes in bone metabolism characterized by a loss in bone mass [1] that may lead to an increased incidence of fractures and poor healing of fractures [1] [2] [3] [4] [5] . The reason for such bone loss in old age is clearly multifactorial. Hormonal, mechanical, and nutritional mechanisms [1] can result both in defects of bone formation as well as increased bone resorption [1, 6, 7] . The clinical bone loss [8] seen in diabetes is also associated with defects in bone formation [9, 10] and increased osteolysis [11, 12] . Proposed mechanisms for these changes in diabetic patients have also included nutritional, hormonal, and vascular factors [13] . However, little experimental support for any proposed mechanism is currently available.
Cross-linking of long-lived proteins such as collagen increases as a function of age. This process of protein crosslinking occurs non-enzymatically, and involves reaction of a sugar with an amino group on the protein. The reactive Amadori products that are formed can then bind with amino groups on other proteins to form advanced glycation end-products (AGEs) through intermolecular crosslinks [14] . This process is greatly accelerated with diabetes [14, 15] , and the resulting cross-linked proteins are thought to contribute to many of the complications associated with diabetes [14] [15] [16] . AGE-formation causes decreased binding of matrix components to each other, and of cells to matrix [17] [18] [19] [20] . Since adhesion of growth factors as well as many types of cells to collagen substrates in bone matrix is essential for growth and proliferation of bone [21] , we postulated that such glycation of the collagenous matrix of bone may result in impaired adhesion of growth factors or osteogenic cells and lead to changes in structure and healing in diabetic bones. In the present study, the hypothesis that matrix glycation alters bone metabolism was tested in a well-established experimental model of demineralized bone-matrix-induced endochondral bone formation [22] [23] [24] .
Materials and methods Materials
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Animals
The experimental protocol was reviewed and approved by the Institutional Animal Care and Use Committee of the Albert Einstein College of Medicine. Adult female rats of the Long-Evans strain were used for matrix preparation, and Long-Evans rats, aged 28-35 days, were used for implantation.
Bone matrix preparation
Bone matrix was prepared from dehydrated diaphyseal shafts of rat femur and tibia. These were pulverized in a CRC micromill (Techni Laboratories, Vineland, N J, USA). Particles were sieved to a size of 74420 btm. The particles were washed in 0.5 N HC1 (25 meq/g) for 3 h, followed by repeated exchanges of water for 2 h, then washed in ethanol for 1 h, and finally in ethyl ether for 30 min. The particles were dried overnight at 37 ~ [24] .
Implantation
In vivo assays of bone-inductive capacity of the matrix was conducted by implanting the matrix (10-20 gg) into subcutaneous pockets in the back of Long-Evans rats (28-35 days old) under general anaesthesia.
Experimental protocols
Experiment I was performed to determine the bone-inductive capacity of the matrix, the effects of glycolaldehyde (GA), and the ability of aminoguanidine (AG) to inhibit the effects of glycolatdehyde. Bone matrix was incubated in three ways: (1) phosphate buffered saline (PBS), (2) 50mmol/1 GA in PBS (GA), and (3) 50 mmol/1 GA and 250 mmol/1 aminoguanidine-HC1 (GA + AG). All incubations were performed for 3 h at 37 ~ After the incubations, a portion of each resultant matrix was assayed by fluorescence for cross-linking. Matrix from each group was also implanted for bioassay of bone inductive properties: (1) PBS (n = 28), (2) GA (n = 12), and (3) GA + AG (n = 12). Fourteen days later, the implants were assayed for bone induction by 45Ca uptake, alkaline phosphatase content, calcium content, and histology as outlined below.
Experiment 2 was performed to determine the ability of sodium cyanoborohydride (NaCNBH~), which chemically reduces Schiff base precursors of AGEs, to inhibit the effects of glycolaldehyde. Bone matrix was incubated in three ways: 1) PBS (PBS), 2) 50 mmol/1 GA in PBS (GA), and 3) 50 mmol/l GA and 50 mmol/1 NaCNBH3 (GA + NaCNBH3). All incubations were performed for 3 h at 37 ~ After the incubations, a portion of each resultant matrix was assayed by fluorescence for cross-linking. Matrix from each group was also implanted for bio-assay of bone inductive properties:
(1) PBS (n = 23), (2) GA (n = 7), and (3) GA + NaCNBH3 (n -12). Fourteen days later, the implants were assayed for bone induction by 45Ca uptake, alkaline phosphatase content, calcium content, and histology as outlined below.
Experiment 3 was performed to determine if application of bone morphogenetic protein 2 (BMP-2), a potent bone-derived morphogenic cytokine, can restore bone-inductive capacity to modified matrix. Bone matrix was incubated in two ways: 1) PBS (PBS), 2) 50 mmol/1 GA in PBS (GA). The incubated material was combined with either 7 btg or 21 t.lg of BMP-2 before implantation. All incubations were performed for 3 h at 37 ~ Matrix from each group was implanted for bio-assay of bone inductive properties: (1) PBS, 7 btg BMP-2 (n = 4), (2) PBS, 21 gg BMP-2 (n = 4), (3) GA, 7 gg BMP-2 (n = 4), and (4) GA, 21 gg BMP-2 (n = 4). Fourteen days later, the implants were assayed for bone induction.
BMP-2 was prepared as previously described [25] . Glycolaldehyde was obtained from Sigma Chemical Co. (St. Louis, Mo., USA) and 45CAC12 from NEN Research Products (Boston, Mass., USA).
Assays
Fluorescence: Fluorescence of the treated and non-treated bone matrix was measured on a Perkin-Elmer LS-3B spectrofluorometer (Norwalk, Conn., USA). Excitation was at 325 nm and emission at 400 nm [26] .
45Calcium uptake: Fourteen days after implantation, 45CaCl; in 0.9 % saline was injected intraperitoneally at a dose of 1 gCi/g body weight 2 h before the rats were killed. The implants were dissected free, weighed, and homogenized in 2ml ice-cold 0.15mol/1 NaC1-3 retool/1NaHCO3. The specimen was centrifuged for 15 rain at 4~ at 20,000 g. The sediment was stirred in 5 ml 0.1 tool/1 CaC12 in 0.05 mol/1 Tris-HC1 at 25 ~ for 30 min. It was then centrifuged at 4500 g for 10 min and washed twice with 10 ml 5 mmol/1 Tris-HC1 (pH 7.4). It was centrifuged again at 4500 g for 5 min, followed by continuous stirring in 10 ml 0.5 mol/1HC1 for 2 h at 25 ~ After centrifuging at 4500 g for 10 rain the sediment was counted.
Alkaline phosphatase: The supernatant from the initial washing with 0.15 mol/1 NaC1 was assayed for alkaline phosphatase activity [27] . In experiments 1 and 2, the alkaline phosphatase was measured in 100 Sigma units (SU)/g tissue, whereas in experiment 3 it was measured in 100 International units (IU)/g tissue.
Calcium content."
The acid soluble fraction of the sediment was assayed for calcium content [28] .
Histology: Specimens were fixed in Bouin's fixative for histologic sections. After imbedding, 1 btm sections were prepared and stained with haematoxylin and eosin.
Statistical analysis
All data are expressed as mean _+ SEM. ANOVA and NewmanKuel's tests were used for the statistical analysis. P less than 0.05 was considered significant. 
Experiment 1
Incubation of the bone matrix with glycolaldehyde increased the amount of A G E products as indicated by increased fluorescence (138 + 6 IU, PBS; 248 _+ 38 IU, GA; p < 0.01) (Fig. 1) . In vivo, this corresponded to a significantly reduced ability to induce bone-formation as measured by calcium content ( 1 7 + 4 g g / m g , PBS; 5 + 2 Bg/mg, G A ; p < 0.05), alkaline phosphatase content (410 + 40 SU/g, PBS; 10 + 1 SU/g, GA; p < 0.01), and 4SCa uptake (6.4 + 1.0 Kcpm/mg, PBS; 0.3 + 0.1 Kcpm/mg, GA; p < 0.01) of the implants (Fig. 2) . This reduction in bone induction was also confirmed by histology (Fig. 3) . Co-incubation with an inhibitor of A G E formation, aminoguanidine, significantly prevented the effects of glycolaldehyde. Aminoguanidine co-incubated matrix did not have an appreciably different fluorescence pattern than PBS controls (Fig. 1) . The bone-inductive effects of Values are given as mean+_SEM; ap<0.05 VS PBS; bp<0.01 VS PBS; Cp < 0.05 GAvs GA + NaCNBH~. PBS, Matrix incubation with phosphate buffered saline before implantation; GA, incubation with 50 mmol/1 glycotaldehyde; GA + NaCNBH3, incubation with glycolaldehyde and 50 retool/1 sodium cyanoborohydride matrix incubated with glycolaldehyde and aminoguanidine was not significantly different from the PBS controls as assayed by calcium content, alkaline phosphatase, 45Ca uptake (Fig. 2 ), or histology (Fig. 3 ). 
Experiment 2
Co-incubation with another inhibitor of AGE formation, NaCNBH3 cyanoborohydride, also significantly prevented the effects of glycolaldehyde. NaCNBH3 co-incubated matrix had a similar fluorescence pattern to PBS controls (Fig. 1) . However, in vivo assays demonstrated a partial reduction of bone-inductive capacity of matrix incubated with both glycolaldehyde and NaCNBH3, suggesting that NaCNBH3-stabilized modifications on matrix amino groups also interfered with normal matrixprotein associations (Table 1) . This reduction in bone-inductive capacity, as measured by calcium content, alkaline phosphatase, 45Ca uptake, or histology of the matrix implants, was not of the same magnitude as that observed after incubation with glycolaldehyde alone.
Experiment 3
Matrix treated with glycolaldehyde lost the ability to induce bone formation. Application of BMP-2 to glycolaldehyde-treated matrix did not restore the bone inductive capacity of the matrix when measured by alkaline phosphatase levels (Fig. 4) or histology (data not shown).
Discussion
Advanced age and diabetes are each a predisposing factor to bone loss [1, 8, 13] . Proposed mechanisms for these derangements in aging include reduction in calcitonin levels, decreased androgen production, malnutrition, altered calcium absorption, and reduced physicaI activity [1] , whereas in diabetes proposed mechanisms include protein malnutrition, secondary hyperparathyroidism, reduction of sex hormones, increased glucocorticoids, diabetic angiopathy, deficiency of bone matrix mucopolysaccharide synthesis [13] , and effects of insulin deficiency on proliferative mesenchymal cells [23] . While defects in bone metabolism in each case will likely prove multifactorial, we hypothesized that glycation of bone proteins could contribute to these bone derangements. Results in the present study clearly show that modification of bone matrix by glycation alters its ability to induce in vivo bone formation. Glycation products are formed through slow, nonenzymatic reactions between sugars and proteins. A compound such as glycolaldehyde reacts with amino groups on a protein via nucleophitic addition to form unstable Schiff base adducts, which undergo rearrangement to form Amadori products. The Amadori products may then react with amino groups on another protein to form AGE's, often through covalent cross-links [14, 29, 30] . The AGEs continue to form on long-lived proteins over time and this accumulation is accelerated in diabetes due to chronic hyperglycaemia [31] [32] [33] [34] . Obstacles to examining accumulation of AGEs in bone proteins and the biologic effects of such accumulation include the inaccessibility of bone and the prolonged time course of AGE formation. We therefore chose to examine the effects of AGE accumulation in a well-accepted experimental model of bone formation [22] [23] [24] using the highly reactive AGE precursor glycolaldehyde [26] . This (x-hydroxyaldehyde is a glucose-derived compound that undergoes Amadori rearrangements and advanced glycation product formation in a manner similar to glucose. However, since glycolaldehyde is much more reactive than glucose, it forms advanced glycation products within hours instead of weeks to months [26] .
In the 1960 s, Huggins and Urist showed that implantation of devitalized and decalcified bone powder in the subcutaneous tissue of animals induced an outgrowth of mesenchymal cells that differentiated into chondrocytes [22] . Subsequently, cartilage is replaced by osteoblasts and eventually haematopoietic cells form [35] . The similarity of this sequence to fracture healing has been recognized. The decalcified matrix powder was subsequently shown to be mostly collagen with an amino acid content rich in proline, hydroxyproline, and glycine. In further studies, the matrix has been resolved into extractable and non-extractable fractions [24] . Separation of these fractions results in loss of, and reconstitution restores, the bone-inductive capacities. The extractable portion has also been resolved into a series of growth factors variously called osteogenin and bone morphogenetic proteins [36, 37] . Many of these growth factors have been cloned [37] and seem to have redundant functions since they can independently restore the bone inductive capacity of the non-extractable portion of bone matrix [37, 38] . It is postulated that these growth factors, in binding to the non-extractable matrix, facilitate mesenchymal cell attachments that lead to bone formation. The observed changes in bone-inductive capacity produced by matrix glycation is most likely due to altered binding of bone associated growth factors since application of recombinant BMP-2 did not restore bone formation. However, an AGE-induced defect in mesenchymal cell binding to the altered matrix may also be responsible.
The current results would seem, at cursory inspection, to be at odds with findings by Landesman and Reddi [39] in a model of experimentally-induced diabetes. These investigators examined the bone-inductive potential of bone matrix from animals with streptozotocin-induced diabetes. In comparisons with bone matrix from control animals, matrix from rats with experimental diabetes of 2 months duration was a superior inducer of bone when assayed on day 11 and equivalent when assayed on day 18. Though the authors conclude that these findings were related to matrix glycation, no formal quantitation of either early or advanced matrix glycation products was performed. It is unlikely, however, that significant quantities of advanced glycation products had formed in a period as short as 2 months. The complex physiologic alterations associated with diabetes further complicate the interpretation of such in vivo experiments. It is precisely because of these difficulties that we have chosen in the current study to specifically alter bone matrix glycation in vitro.
Certain agents have been shown to block the formation of AGEs. NaCNBH3 selectively reduces reactive Schiff bases, thus stabilizing covalent adducts and inhibiting formation of AGEs [26] . Aminoguanidine inhibits AGE formation primarily by reacting with Amadori-derived intermediates in solution [40] . Aminoguanidine has been shown to dramatically attenuate a number of characteristic diabetic complications in experimental models [41] [42] [43] . The current study demonstrates that AGE-inhibition also blocks sugar-induced defects in matrix-induced bone differentiation. Thus, AGE inhibitors, such as aminoguanidine, may have a therapeutic role in the modulation of bone alterations associated with diabetes and aging.
